Press release
Axial Spondyloarthritis (axSpA) Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033
Axial Spondyloarthritis (axSpA) Market
The Business Research Company offers in-depth market insights through Axial Spondyloarthritis axSpA Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see strong growth in the next few years. It will grow to $8.18 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancements in biomarker identification, tailored therapies, digital health integration, expanded treatment options, healthcare policy support:. Major trends in the forecast period include early intervention strategies, patient-centric care, telemedicine and remote consultations, research on disease mechanisms, shared decision-making.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp
Market Segmentation:
The axial spondyloarthritis (axspa) market covered in this report is segmented -
1) By Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores
Major Driver - Rising Prevalence Of Axial Spondyloarthritis (AXSPA) Is A Catalyst For Market Growth And Advancements In Treatment
The increasing prevalence of spondyloarthritis is expected to propel the growth of the axial spondyloarthritis (axSpa) market going forward. Spondyloarthritis is a chronic illness that typically affects the axial skeleton, including the spine and sacroiliac joints. The rising cases of spondyloarthritis (axSpA) can be associated with the increasing aging population and spine injuries from even minor falls or other accidents, where various treatments are provided for pain management, inflammation control, and enhancing the patient's quality of life suffering from axSpA. For instance, in June 2023, according to Versus Arthritis's Musculoskeletal Health Report 2023, a UK-based charity dedicated to supporting people with arthritis, as of the year 2022, around 60,000 individuals were afflicted with axial spondyloarthritis, and annually, approximately 2,200 adults receive a new diagnosis for this condition. Therefore, the increasing prevalence of axial spondyloarthritis (axSpa) is driving the growth of the axial spondyloarthritis (axSpa) market.
Competitive Landscape:
Major companies operating in the axial spondyloarthritis (axspa) market report are Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC, Celgene Corporation, Pozen Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report
Top Trend - UCB Sa Secures Eu Approval For Bimzelx In Treating Axial Spondyloarthritis (AXSPA)
Product innovations are the key trend gaining popularity in the axial spondyloarthritis (axSpA) market. Major companies operating in the axial spondyloarthritis (axSpA) market are developing new drugs to sustain their position in the market. For instance, in June 2023, UCB SA, a Belgium-based pharmaceutical company, received approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This medication is used to treat adults with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) with objective signs of inflammation as indicated by elevated C-reactive protein. These European Union (EU) authorizations represent the drug's first global marketing licenses for axial spondyloarthritis.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Axial Spondyloarthritis axSpA Market Characteristics
3. Axial Spondyloarthritis axSpA Market Trends And Strategies
4. Axial Spondyloarthritis axSpA Market - Macro Economic Scenario
5. Axial Spondyloarthritis axSpA Market Size And Growth
…..
27. Axial Spondyloarthritis axSpA Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-mode
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Axial Spondyloarthritis (axSpA) Market 2024 Report By Key Companies, Regional Analysis And Forecast 2033 here
News-ID: 3434254 • Views: …
More Releases from The Business research company
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the M …
The meal replacement market is gaining significant momentum as consumer preferences shift toward convenient and health-focused nutrition solutions. With rising awareness about preventive healthcare and personalized diets, this sector is set for considerable expansion. Let's explore how the market size is expected to evolve, who the key players are, emerging trends, and the main segments driving this growth.
Projected Growth Trajectory of the Meal Replacement Market Size
The meal replacement…
Leading Companies Reinforcing Their Presence in the Malted Barley Market
The malted barley industry is positioned for steady expansion as demand grows across various sectors. With increasing interest from craft brewers and functional food producers, this market is set to experience meaningful growth driven by innovation and sustainability efforts. Let's dive into the current market size, key players shaping the industry, trends influencing its trajectory, and detailed segment insights.
Projected Market Size and Growth Outlook of the Malted Barley Market …
Future Perspective: Key Trends Shaping the Low-calorie Food Market up to 2030
The low-calorie food market is poised for significant expansion as consumer preferences shift toward healthier eating habits and more personalized nutrition options. Advances in product innovation and supportive regulatory frameworks are expected to drive rapid growth over the coming years. Here's an overview of the market size, key players, emerging trends, and segmentation shaping this evolving industry.
Projected Expansion of the Low-calorie Food Market Size Through 2030
The low-calorie food…
Competitive Landscape: Leading Companies and New Entrants in the Liquid Nutritio …
The liquid nutritional supplement sector is on the rise, driven by evolving consumer preferences and innovations in health and wellness. With growing awareness about personalized nutrition and preventive healthcare, this market is set to witness substantial growth over the coming years. Let's explore the market's projected size, major players, emerging trends, and key segments shaping this dynamic industry.
Projected Market Value and Growth Trajectory of the Liquid Nutritional Supplement Market …
More Releases for Spondyloarthritis
Axial Spondyloarthritis Market Projected to Reach USD 5 Billion by 2034
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints. It includes both radiographic axSpA (ankylosing spondylitis, AS) and non-radiographic axSpA (nr-axSpA). Symptoms such as chronic back pain, stiffness, and fatigue severely impact quality of life, often emerging in young adults.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71307
Over the past two decades, management of axSpA has advanced significantly, moving from NSAIDs and…
Axial Spondyloarthritis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Axial Spondyloarthritis Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Axial Spondyloarthritis Research. Learn more about…
Axial Spondyloarthritis (axSpA) Industry - Key Market Dynamics and Trends
The axial spondyloarthritis (axspa) market size has grown strongly in recent years. It will grow from $5.54 billion in 2023 to $6.04 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to improved diagnostic criteria, biological treatment advancements, rising disease awareness, genetic research advances, clinical trial progress.
The axial spondyloarthritis (axspa) market size is expected to see…
Axial Spondyloarthritis Drug Market to see Rapid Growth by 2029
The global axial spondyloarthritis drug market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period. The market is primarily driven by favourable conditions for pharmaceutical producers and the attention of various government agencies on enhancing the current healthcare infrastructure. These will lead to a rise in global demand for various drugs for treatment options for axial spondyloarthritis in the near future. Additionally, significant investment in research and…
Optimization Of Workflows To Catalyse The Axial Spondyloarthritis Treatment Mark …
Axial spondyloarthritis is a type of inflammatory arthritis which primarily affects the axial skeleton such as pelvic joints and spine. Generally ankylosing spondylitis (AS), an inflammatory disease of the sacroiliac joints and spine are collectively termed as axial spondyloarthritis.
The axial spondyloarthritis is divided in two stages namely non- radiographic and radiographic stage. Severe and chronic back pain is the major symptom of this complication along with buttock pain and pain…
Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017
"The Report Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Axial Spondyloarthritis Market
Summary
GlobalData's clinical trial report, Axial Spondyloarthritis Global Clinical Trials Review, H1, 2017" provides an overview of Axial Spondyloarthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Axial Spondyloarthritis. Report includes an overview of trial…
